LeMaistre C F, Saleh M N, Kuzel T M, Foss F, Platanias L C, Schwartz G, Ratain M, Rook A, Freytes C O, Craig F, Reuben J, Nichols J C
South Texas Cancer Institute, San Antonio 78229, USA.
Blood. 1998 Jan 15;91(2):399-405.
The purpose of this study was to evaluate the safety, tolerability, pharmacokinetics, and possible antitumor activity of a ligand fusion-protein, DAB389IL-2, in a phase I trial. This was a multicenter, open-label, dose-escalation trial. Patients with preserved organ function and histologically confirmed relapsed cutaneous T-cell lymphoma (CTCL), other non-Hodgkin's lymphomas (NHL), or Hodgkin's disease (HD) were eligible if their cancer was shown to express the interleukin (IL)-2 receptor by an immunohistochemical assay for the p55 or the p75 subunit. Patients received up to eight courses of DAB389IL-2 given as a short intravenous infusion daily for 5 days with subsequent courses every 21 days. The maximum tolerated dose (MTD) and tumor response was determined according to standard criteria. Seventy-three patients (44 men/29 women), aged 16 to 81 years (mean, 50.7) with CTCL (n = 35), NHL (n = 17), and HD (n = 21) were enrolled. The patients were extensively treated, failing 0 to 15 previous therapies (median, 4). Patients received one to six courses (mean, 3.3) of DAB389IL-2 over a range of 3 to 31 micrograms/kg/day. The dose-limiting toxicity was asthenia, establishing the maximum tolerated dose of 27 micrograms/kg/day. Approximately half of all patients had significant titers of antibody to diphtheria toxin or to DAB389IL-2 at the time of enrollment compared with 92% with titers at the end of treatment. The presence of antibody did not preclude clinical response. There were five complete (CR) and eight partial (PR) remissions in patients with CTCL with one CR and two PR occurring in NHL. The median time to response was 2 months and the duration of response was 2 to 39+ months. No responses were documented in patients with HD. DAB389IL-2 is well tolerated with an MTD of 27 micrograms/kg/day. This ligand fusion-protein showed antitumor effects in patients with IL-2 receptor expressing CTCL and NHL. Additional trials in these diseases are warranted.
本研究的目的是在一项I期试验中评估配体融合蛋白DAB389IL-2的安全性、耐受性、药代动力学及可能的抗肿瘤活性。这是一项多中心、开放标签、剂量递增试验。器官功能保留且经组织学确诊为复发性皮肤T细胞淋巴瘤(CTCL)、其他非霍奇金淋巴瘤(NHL)或霍奇金病(HD)的患者,如果其癌症通过针对p55或p75亚基的免疫组织化学检测显示表达白细胞介素(IL)-2受体,则符合入选标准。患者接受多达八个疗程的DAB389IL-2治疗,每天静脉短时间输注5天,随后每21天进行下一疗程。根据标准标准确定最大耐受剂量(MTD)和肿瘤反应。纳入了73例患者(44例男性/29例女性),年龄16至81岁(平均50.7岁),其中CTCL患者35例,NHL患者17例,HD患者21例。这些患者接受过广泛治疗,之前失败了0至15次治疗(中位数为4次)。患者接受了1至6个疗程(平均3.3个疗程)的DAB389IL-2治疗,剂量范围为3至31微克/千克/天。剂量限制性毒性为乏力,确定最大耐受剂量为27微克/千克/天。大约一半的患者在入组时对白喉毒素或DAB389IL-2有显著滴度的抗体,而在治疗结束时这一比例为92%。抗体的存在并不妨碍临床反应。CTCL患者中有5例完全缓解(CR)和8例部分缓解(PR),NHL患者中有1例CR和2例PR。缓解的中位时间为2个月,缓解持续时间为2至39+个月。HD患者中未记录到缓解情况。DAB389IL-2耐受性良好,最大耐受剂量为27微克/千克/天。这种配体融合蛋白在表达IL-2受体的CTCL和NHL患者中显示出抗肿瘤作用。有必要在这些疾病中开展进一步试验。